Prophylactic Treatment Challenges and Considerations for Hemophilia A

EP: 1.Management Insights for Patients With Hemophilia

EP: 2.Coverage Decisions for Expensive Hemophilia Treatments

EP: 3.Impact of ICER Reports on Hemophilia Treatment Decisions

EP: 4.Enhancing Provider Access and Expertise for Rare Disease Care

EP: 5.Factors Impacting Hemophilia A Care Costs

EP: 6.Collaborative Strategies in Hemophilia A Care Cost Management

EP: 7.Strategies to Manage Medication Costs and Waste

EP: 8.Adapting to Novel Hemophilia A Treatments

EP: 9.Comprehensive Insights into Hemophilia A: Prevalence, Clinical Impact, and Economic Considerations

EP: 10.Evolution of the Hemophilia A Treatment Landscape: Innovations and Guidelines

EP: 11.Hemophilia A Treatment Factors and Outcomes

Now Viewing

EP: 12.Prophylactic Treatment Challenges and Considerations for Hemophilia A

EP: 13.Consequences of Nonadherence in Hemophilia A

EP: 14.Advancements in Hemophilia A Therapies

EP: 15.Comparing Hemophilia A Therapies: Efficacy and Safety Insights

EP: 16.Real-World Insights: Factor vs Emicizumab in Hemophilia A

EP: 17.Emicizumab Dosing: Prophylaxis and Bleeding Management

EP: 18.Optimizing Hemophilia Treatment: Strategies and Adherence

EP: 19.Advancements in Hemophilia A Therapies: Altuviiio and Roctavian

EP: 20.Advancements in Hemophilia A Treatment: Fitusiran and the Evolving Landscape

This is a video synopsis/summary of an Insights involving Allison Wheeler, MD.

Wheeler addresses the nuanced considerations for implementing prophylaxis in patients with mild to moderate hemophilia A, stressing a personalized approach based on bleeding events and developmental milestones. While early initiation, typically around middle school or high school when sports involvement increases, is crucial, Wheeler highlights situational prophylaxis for those engaging in aggressive activities, preventing traumatic bleeds. Notably, patients with significant joint bleeds necessitate prophylaxis to preserve joint integrity.

Transitioning to challenges associated with prophylactic treatment, Wheeler notes historical difficulties in intravenous administration, particularly for infants, mitigated by subcutaneous factor VIII mimetic. Practical challenges encompass dosing frequency impact on adherence. Acknowledging the multifactorial nature, she discusses individual preferences regarding treatment regularity. Moreover, Wheeler highlights issues like insurance coverage and product cost, recognizing the evolving landscape with newer products and varying insurance situations. Overall, she emphasizes the critical role of tailored approaches, considering each patient’s circumstances for effective hemophilia A management.

Video synopsis is AI-generated and reviewed by AJMC^® editorial staff.